Chemomab Therapeutics Ltd at JMP Securities Life Sciences Conference Transcript
My name is Jon Wolleben, Senior Analyst here at JMP. And we're pleased to have the team from Chemomab -- and CEO, Dale Pfost, who will be giving us an overview of the company. This is a first-in-class novel mechanism that's going after two really hard to treat diseases with high unmet need. So -- interested to dig in a little bit this morning and we'll save time for questions at the end. So thank you, Dale.
Thank you. Please refer to our forward-looking statements and risk factors, including those on file with the SEC. Chemomab is a clinical-stage biotech company. Our focus is developing innovative therapies for rare, inflammatory and fibrotic disease with high unmet need. We believe we have a unique story with substantial clinical and commercial potential.
CM-101 is a pipeline in a product, and is a first-in-class monoclonal antibody that neutralizes CCL24, a novel target at the confluence of fibrosis and inflammation. Our clinical program is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
